Last checked at 22 May 2024 22:59
What to know about bird flu in dairy cows and the risk to humans
CHICAGO, May 22 (Reuters) -
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News
GSK Share
Chat
GSK Share
Trades1,468
GSK
Live RNS
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions
GSK
Media
Glaxosmithkline Information
Share Price Information for Glaxosmithkline (GSK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,805.00
Bid:
1,804.50
Ask:
1,805.50
Change:
16.50 (0.92%)
Spread:
1.00 (0.055%)
Open:
1,796.00
High:
1,808.50
Low:
1,793.50
Prev. Close:
1,788.50
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.GlaxoSmithKline's Relvar Ellipta shows 'significant' test score for COPD
Mon, 05th Sep 2016 07:08
(ShareCast News) - Tests of a GlaxoSmithKline respiratory drug have found a statistically significant reduction in the rate of attacks suffered by chronic obstructive pulmonary disease (COPD) patients compared to when they receive the standard treatment. The pioneering Salford Lung Study by GSK and its partner on this drug Innoviva, also showed a similar improvement against patients who were taking a medicine in the same class as Relvar Ellipta, known as Breo Ellipta in the US.The drug, which was jointly developed by Innoviva and GSK and will see Innoviva receive associated royalty revenues if approved and commercialized, was tested in 2802 patients with COPD in the randomised controlled trial in various hospitals in Manchester and Salford, which is being followed by a second Salford Lung Study currently being conducted in patients with asthma, with results expected in 2017.Neil Barnes, GSK's global medical head of respiratory, explained that the study included a broad spectrum of patients who had minimal interventions "to see if this would allow us to observe a difference between treatments". "The results from SLS provide robust evidence that will enable the healthcare community to begin to understand how the choice of COPD treatment can significantly influence patient outcomes. We are continuing to analyse the data from the study as we know there is so much more we will learn and we look forward to sharing our findings in future publications."Innoviva chief Michael Aguiar said the study confirmed the effectiveness of Relvar Ellipta "compared with not only usual care, but also with those patients who were taking a different medicine in the same ICS/LABA class. These are important data to share with physicians, from a unique study carried out in conditions closely reflecting everyday clinical practice."
More News
21 May 2024 11:23
AstraZeneca aims for $80 bln in total revenue by 2030
Sees $80 bln in 2030 revenue by 2030
*Read more21 May 2024 08:49
GSK's depemokimab asthma treatment meets endpoints in latest trials
(Alliance News) - GSK PLC on Tuesday announced positive results from trials of depemokimab, an "ultra-long-acting biologic" that could simplify treatment options for patients with severe asthma.
Read more21 May 2024 07:21
GSK reports promising results from asthma treatment trials
(Sharecast News) - GSK announced promising results from phase three clinical trials evaluating the efficacy and safety of depemokimab in treating severe asthma with type 2 inflammation on Tuesday.
Read more20 May 2024 16:11
IN BRIEF: GSK executive buys GBP20,026 worth shares
GSK PLC - London-based pharmaceuticals firm - Senior Vice President, Global Communications & Chief Executive Office, Sally Jackson, buys 1,120 shares at 1,788 pence each. Worth total GBP20,026.
Read more17 May 2024 17:38
London's FTSE nudges lower for week after record run
Haleon falls after GSK offloads remaining stake
*Read more17 May 2024 15:52
London close: Stocks recoup some earlier losses
(Sharecast News) - London stocks remained in negative territory by Friday's close, although they managed to recoup some of the losses seen earlier in the session as Wall Street opened with positive momentum.
Read more17 May 2024 11:52
LONDON MARKET MIDDAY: FTSE 100 slides; Eurozone inflation steady
(Alliance News) - Stock prices in London were lacklustre at midday on Friday, as investors eye the trajectory of interest rates across the globe.
Read more17 May 2024 09:03
TOP NEWS: GSK sells remaining Haleon stake for GBP1.25 billion
(Alliance News) - GSK PLC on Friday said it has sold its remaining shares in Haleon PLC, marking a total exit from its consumer healthcare spin-off.
Read more17 May 2024 08:56
LONDON MARKET OPEN: FTSE 100 lacklustre as Wall Street rally ends
(Alliance News) - Stock prices in London opened lower on Friday, after Thursday saw Wall Street's rally end in a record breaking session.
Read more17 May 2024 08:39
GSK raises $1.5 bln from sale of remaining Haleon stake
May 17 (Reuters) - British drugmaker GSK has raised 1.25 billion pounds ($1.52 billion) from a sale of its remaining stake in consumer healthcare company Haleon to institutional investors.
Read more17 May 2024 07:42
LONDON BRIEFING: Land Securities ups dividend; GSK sells Haleon stake
(Alliance News) - Stocks in London are called to open lower, as investors wait for an inflation reading from the eurozone later this morning.
Read more17 May 2024 07:29
GSK raises £1.25bn from sale of remaining Haleon stake
(Sharecast News) - GSK said on Friday that it has sold its remaining 4.2% stake in consumer health business Haleon, which it spun off in July 2022.
Read more16 May 2024 17:33
FTSE 100 ends lower on disappointing corporate updates, BT Group soars
BT Group up after CEO aims for more than double free cash flow
*Read more16 May 2024 17:13
TOP NEWS: GSK to sell remaining holding in spin-off Haleon
(Alliance News) - GSK PLC on Thursday said it intends to sell its remaining stake in Haleon PLC, the consumer healthcare firm it spun out almost two years ago.
Read more